NO983410L - FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon - Google Patents

FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon

Info

Publication number
NO983410L
NO983410L NO983410A NO983410A NO983410L NO 983410 L NO983410 L NO 983410L NO 983410 A NO983410 A NO 983410A NO 983410 A NO983410 A NO 983410A NO 983410 L NO983410 L NO 983410L
Authority
NO
Norway
Prior art keywords
hepatitis
procedures
treatment
patients affected
consensus interferon
Prior art date
Application number
NO983410A
Other languages
English (en)
Norwegian (no)
Other versions
NO983410D0 (no
Inventor
Lawrence M Blatt
Michael Klein
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO983410D0 publication Critical patent/NO983410D0/no
Publication of NO983410L publication Critical patent/NO983410L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO983410A 1996-02-05 1998-07-23 FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon NO983410L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/595,440 US5980884A (en) 1996-02-05 1996-02-05 Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
PCT/US1997/000340 WO1997027866A1 (en) 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon

Publications (2)

Publication Number Publication Date
NO983410D0 NO983410D0 (no) 1998-07-23
NO983410L true NO983410L (no) 1998-10-05

Family

ID=24383236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983410A NO983410L (no) 1996-02-05 1998-07-23 FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon

Country Status (15)

Country Link
US (1) US5980884A (cs)
EP (1) EP0879059A1 (cs)
JP (1) JP2000504010A (cs)
KR (1) KR19990082084A (cs)
CN (1) CN1217660A (cs)
AU (1) AU1531897A (cs)
BR (1) BR9700829A (cs)
CZ (1) CZ231998A3 (cs)
EA (1) EA199800674A1 (cs)
HU (1) HUP9900929A3 (cs)
IL (1) IL125494A0 (cs)
NO (1) NO983410L (cs)
SK (1) SK101798A3 (cs)
WO (1) WO1997027866A1 (cs)
ZA (1) ZA97721B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000506839A (ja) * 1996-02-28 2000-06-06 アイエフアイ ノスチチュート ファルマコテラピコ イタリアーノ ソシエタ ペル アチオニ 天然ヒトα―インターフェロンを含む薬剤組成物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
BR0212928A (pt) * 2001-09-28 2004-10-13 Intermune Inc Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
CA2460690A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
AR036727A1 (es) * 2001-10-05 2004-09-29 Intermune Inc Composiciones farmaceuticas para el tratamiento de la fibrosis hepatica y de la infeccion causada por el virus de la hepatitis c y uso de dicha composicion para la manufactura de un medicamento
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
AU2003217402A1 (en) * 2002-02-14 2003-09-04 Pharmasset Inc Modified fluorinated nucleoside analogues
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312286A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
PT1576138T (pt) 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
US20050208019A1 (en) * 2003-08-28 2005-09-22 Guangwen Wei Uses of interferons with altered spatial structure
CA2540858C (en) 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
KR20070011451A (ko) 2004-05-05 2007-01-24 예일 유니버시티 신규의 항바이러스 헬리오크산틴 유사체
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CA2580457C (en) 2004-09-14 2014-11-04 Pharmasset, Inc. Preparation of 2'­fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1868636A4 (en) * 2005-03-09 2012-03-28 Guangwen Wei USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS
EP2103623A3 (en) 2005-07-25 2009-12-16 Intermune, Inc. Novel macrocyclic inhibitors of Hepatitis C virus replication
JP2009511595A (ja) 2005-10-11 2009-03-19 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルスの複製を阻害する化合物および方法
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
MX2011006892A (es) 2008-12-23 2011-07-20 Pharmasset Inc Sintesis de nucleosidos de purina.
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
ES2551944T3 (es) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI726291B (zh) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
SI3650014T1 (sl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
SK101798A3 (en) 2000-03-13
CZ231998A3 (cs) 1999-03-17
HUP9900929A3 (en) 1999-11-29
EA199800674A1 (ru) 1999-02-25
BR9700829A (pt) 1998-07-07
JP2000504010A (ja) 2000-04-04
US5980884A (en) 1999-11-09
IL125494A0 (en) 1999-03-12
AU1531897A (en) 1997-08-22
EP0879059A1 (en) 1998-11-25
KR19990082084A (ko) 1999-11-15
CN1217660A (zh) 1999-05-26
WO1997027866A1 (en) 1997-08-07
ZA97721B (en) 1997-08-01
HUP9900929A2 (hu) 1999-07-28
NO983410D0 (no) 1998-07-23

Similar Documents

Publication Publication Date Title
NO983410D0 (no) FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
FI20080432L (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
NO955291D0 (no) System for viral inaktivering av blod
EP0759979A4 (en) THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS
NO975775D0 (no) Fremgangsmåte for fremstilling av forbindelser med antifugal aktivitet
EP0707855A3 (en) Combination therapy for chronic hepatitis C infection
NO172217C (no) Anlegg for behandling av borekaks
AP9801346A0 (en) Xanthone analogs for the treatment of infectious diseases
NO964006L (no) Fremgangsmåte for kontinuerlig koking av vörter
NO986177D0 (no) FremgangsmÕte for fremstilling av terapeutisk DNA
AU5157998A (en) Methods and compositions for treatment of hepatitis c infection
FI925261A7 (fi) Virushepatiitin diagnoosi ja hoito
AU3530293A (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
NO914997D0 (no) Fremgangsmaate ved behandling av sandstensformasjoner
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
ID21369A (id) Komposisi farmasi untuk penyembuhan penyakit yang disebabkan oleh virus
GB9425604D0 (en) Peptides effective for diagnsis of hepatitis C infection
AU7716900A (en) Hcv e2 protein binding agents for treatment of hepatitis c virus infection
ZA932271B (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
DK17491D0 (da) Sugeindretning til anvendelse ved tandbehandling
DK401589D0 (da) Fremgangsmaade ved behandling af slagtekroppe ellerdele deraf
DE19980730D2 (de) Radioimmunpharmaka zur Therapie der Hepatitis C
GB9621866D0 (en) Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of hepatitis B virus infection and leprosy
BG98272A (en) Preparation and method for the treatment of virus hepatitis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application